Careismatic Brands Launches “19 Days of Gratitude” Global Campaign to Support Nurses and the DAISY Foundation
24.9.2020 16:00:00 EEST | Business Wire | Press release
Careismatic Brands, the world’s largest designer and manufacturer of medical apparel, today announced the launch of a global tribute and charitable fundraising campaign, “19 Days of Gratitude,” spotlighting the heroism of nurses as they continue to battle COVID-19 on the front lines. Launching in a year that the World Health Organization has deemed “The International Year of The Nurse and Midwife,” and timed to the 200th anniversary of Florence Nightingale’s birth, the new campaign will celebrate nurses by revealing 19 stories that showcase frontline nurses from around the world over 19 consecutive days. The campaign will debut on careismatic.com/TributeToCourage and across Careismatic’s various social and digital channels, to celebrate the nursing community and raise money for the DAISY (Diseases Attacking the Immune System) Foundation, a worldwide organization recognizing the incredible work and sacrifice of nurses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005263/en/
Medical apparel manufacturer, Careismatic Brands, launches global campaign to pay tribute to nurses and raise funds for the DAISY Foundation (Graphic: Business Wire)
The campaign will kick off with a powerful tribute video “In The Year of The Nurse – A Tribute to Courage,” shot and produced by Hollywood creative agency Mob Scene. The video features a reimagined recording of George Harrison’s classic song, “Give Me Love (Give Me Peace on Earth)” from Grammy Award-winning music producer Rob Cavallo (former Chairman of Warner Bros. Records, whose accolades include 1988 Producer of the Year; 2005 Record of the Year for Green Day’s Boulevard of Broken Dreams; and selling in excess of 160 million records worldwide). Cavallo’s version of “Give Me Love (Give Me Peace on Earth)” features children singing from home and is designed to recognize and uplift health care professionals during this pandemic.
“Health care professionals are selfless people who are putting themselves on the line to save people’s lives during this COVID-19 crisis and this campaign is a tribute to them,” said Michael Singer, CEO of Careismatic Brands. “Our mission at Careismatic Brands is to champion the people behind the scrubs, and we are honored to share this very meaningful tribute as a way to thank the people who have given so much hope and professional care – at much personal risk – to so many COVID patients during these extraordinary times.”
Cavallo rerecorded the song during the middle of the pandemic’s stay-at-home mandate, so he was forced to creatively develop a process of overlaying each individual singer’s track while working remotely with engineers and musicians.
“We kept coming back to Give Me Love’s lyrics, which are incredibly meaningful and exactly what people need to hear during these unprecedented times,” Cavallo said. “George Harrison found the song to be profoundly moving and described it as a prayer and personal statement between him, the Lord and whoever likes it. If our version of this beautiful classic can brighten one nurse’s day after the incredible sacrifice they are making, it is all worth it.”
The video ends by encouraging viewers to donate to the DAISY Foundation. The fundraising effort will support their traditional programs as well as a new initiative awarding nurses grants to advance health equity in underserved communities.
“Careismatic Brands has been a longtime supporter of the DAISY Foundation and our mission to award and celebrate nurses as the unsung heroes providing quality health care,” said Bonnie Barnes, Co-Founder of the DAISY Foundation. “When we first saw the ‘Tribute to Courage’ video and heard its score with the plea for love and hope, we were immediately struck by its power and ability to provide a much-needed lift to nurses during this incredibly difficult time. We are thrilled that Careismatic Brands will be bringing this important tribute to nurses and offering a fundraising opportunity to the public,” Barnes continued. “Donations will fund nurse recognition as well as important research done by nurses to ensure that all people, no matter their race or economic situation, receive high-quality health care.”
Careismatic Brands’ “19 Days of Gratitude” campaign comes on the heels of the company’s $1 million donation of its Cherokee Uniforms and Dickies Medical branded scrubs to health care workers. The company delivered scrubs to more than 200 hospitals, in areas most impacted by the virus, to help health care workers lacking personal protective equipment get the apparel they needed to either change or even dispose of their scrubs throughout the day to avoid viral spread.
For more information on how to access the campaign, music video, 19 stories from nurses around the globe and to donate, please visit careismatic.com/TributeToCourage.
ABOUT CAREISMATIC BRANDS
Careismatic Brands, Inc. (formerly Strategic Partners, Inc.) is the global leader in medical apparel with a distribution footprint in more than 70 countries, and a deep portfolio of top-selling medical apparel, footwear and accessories brands such as Cherokee Uniforms, Dickies Medical, heartsoul, Infinity by Cherokee, ScrubStar, Tooniforms and Anywear. Plus innovative and game-changing wellbeing brands such as Certainty SmartBoost, an antimicrobial laundry additive that works alongside regular detergent to protect fabrics. Careismatic Brands’ portfolio of deeply trusted brands delivers best-in-class products and unparalleled service to distribution partners and consumers.
In addition to being the marketshare leader in medical apparel, Careismatic Brands is a manufacturer/distributor of school uniforms by Classroom, corporate identity uniforms, adaptive clothing by Silverts, medical instruments and accessories. The company takes great care to understand and provide products that champion the people wearing uniforms who serve and care for others. For more information on Careismatic Brands, visit www.careismatic.com and follow us on Facebook and Instagram.
ABOUT DAISY
The DAISY Foundation™ is the leading international organization for nursing recognition. It was created in 1999 by the family of J. Patrick Barnes, in memory of the extraordinary nursing care they experienced when he was in the hospital for 2 months with an auto-immune disease. (DAISY stands for Diseases Attacking the Immune SYstem). His family’s drive to say “thank you” to nurses for the compassionate and skillful care they provide every day – The DAISY Award® for Extraordinary Nurses – has grown to become a highly respected and international nurse recognition program. It provides unique and meaningful recognition that benefits nurses and the organizations where they work.
Today, over 4,500 healthcare organizations and schools of nursing in 29 countries are committed to honoring their nurses with The DAISY Award. Over 1.8 million nurses have been nominated by their patients, families and colleagues, and over 144,000 awards have been granted.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005263/en/
Contact information
Sara Rosales
Careismatic Brands
srosales@strategicpartners.net
310/413-2413 (mobile)
Rachel Rogers
The Acceleration
rachel.rogers@theacceleration.com
310/770-4917 (mobile)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
